Discontinued — last reported Q4 '25
D&A
Thermo Fisher Scientific D&A increased by 28.6% to $292.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 3.9%, from $304.00M to $292.00M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 6.0% CAGR.
Analysis
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
depreciation_and_amortization_cfHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $211.00M | $205.00M | $217.00M | $250.00M | $236.00M | $244.00M | $256.00M | $253.00M | $270.00M | $269.00M | $276.00M | $285.00M | $276.00M | $291.00M | $304.00M | $276.00M | $256.00M | $227.00M | $292.00M |
| QoQ Change | — | -2.8% | +5.9% | +15.2% | -5.6% | +3.4% | +4.9% | -1.2% | +6.7% | -0.4% | +2.6% | +3.3% | -3.2% | +5.4% | +4.5% | -9.2% | -7.2% | -11.3% | +28.6% |
| YoY Change | — | — | — | — | +11.8% | +19.0% | +18.0% | +1.2% | +14.4% | +10.2% | +7.8% | +12.6% | +2.2% | +8.2% | +10.1% | -3.2% | -7.2% | -22.0% | -3.9% |
Business Segments
| Segment | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | — | — | — | — | — | $115.00M | $165.00M | $186.00M |
| Life Sciences Solutions | $55.00M | $58.00M | $59.00M | $59.00M | $56.00M | $62.00M | $74.00M | $70.00M |
| Analytical Instruments | $23.25M | $25.00M | $27.00M | $24.00M | $26.00M | $26.00M | $28.00M | $26.00M |
| Specialty Diagnostics | $21.50M | $29.00M | $32.00M | $22.00M | $23.00M | $23.00M | $23.00M | $24.00M |
| Laboratory Productsand Services | $167.25M | — | — | — | — | — | — | — |
| Total | $276.00M | $291.00M | $304.00M | $276.00M | $256.00M | $227.00M | $292.00M | — |
Laboratory Productsand Services is derived from annual filings.
Laboratory Productsand Services was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's d&a?
- Thermo Fisher Scientific (TMO) reported d&a of $292.00M in Q4 2025.
- How has Thermo Fisher Scientific's d&a changed year-over-year?
- Thermo Fisher Scientific's d&a decreased by 3.9% year-over-year, from $304.00M to $292.00M.
- What is the long-term trend for Thermo Fisher Scientific's d&a?
- Over 4 years (2021 to 2025), Thermo Fisher Scientific's d&a has grown at a 6.0% compound annual growth rate (CAGR), from $831.00M to $1.05B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.